Article

Characteristics of Primary Bradyarrhythmia in Hypertrophic Cardiomyopathy: A 10-Year, Single-Center Analysis

Hong-Da Zhang, Min Tang and Jing-Tao Zhang *

Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China

* Correspondence: zhangjt96@126.com; Tel.: +86-186-0058-1388

Abstract: Background: Secondary bradyarrhythmias in hypertrophic cardiomyopathy (HCM) have been extensively reported. The prevalence and characteristics of primary bradyarrhythmias in HCM have yet to be investigated. Methods: We retrospectively enrolled 101 consecutive patients with HCM who were referred to the arrhythmia center from May 2010 to October 2020. The clinical features of patients with bradyarrhythmias were analyzed. Results: Twenty-nine (28.7%) patients had primary bradyarrhythmias, and six (5.9%) patients had secondary third-degree atrioventricular block (AVB). Of the 29 patients, 17 (58.6%) had sinus node dysfunction (SND), 14 (48.3%) had AVB, and two (6.9%) had both SND and AVB. The median age was 62 years old, and 69% were male. Six (20.7%) patients had left ventricular obstructive outflow tract obstruction, 15 (51.7%) had a history of syncope, and one (3.4%) had a family history of HCM. Most patients (86.2%) had New York Heart Association functional class I or II, and the median left ventricular ejection fraction was 63%. A total of 22 patients received pacemaker implantation, including 17 (77.3%) dual-chamber pacing, four (18.2%) single-chamber ventricular pacing, and one (4.5%) cardiac resynchronization therapy. Conclusions: Primary bradyarrhythmias need to be evaluated in HCM patients with arrhythmia-related symptoms. Patients with HCM might need pacemaker implantation for primary bradyarrhythmias.

Keywords: hypertrophic cardiomyopathy; bradyarrhythmia; pacemaker implantation

1. Introduction

Patients with hypertrophic cardiomyopathy (HCM) often experience different kinds of arrhythmias, including both tachyarrhythmias and bradyarrhythmias [1,2]. Atrial fibrillation is the most common, and ventricular fibrillation is the most fatal arrhythmia in HCM, and they have been extensively investigated [1–4]. Symptomatic bradycardia caused by sinus node dysfunction (SND) and atrioventricular block (AVB) is relatively uncommon in HCM [2]. Most studies on bradycardia focused on secondary third-degree AVB after either ventricular septal myectomy (the Morrow procedure) or percutaneous septal alcohol or radiofrequency ablation [5]. Few studies have evaluated the primary bradyarrhythmias in HCM. This study aimed to comprehensively investigate the characteristics of primary bradyarrhythmias in patients with HCM. The prevalence and characteristics of primary bradyarrhythmias in hypertrophic cardiomyopathy (HCM) have yet to be investigated. The results show that 29 (28.7%) of the enrolled patients with HCM had primary bradyarrhythmias. We suggest that primary bradyarrhythmias be evaluated in HCM patients with arrhythmia-related symptoms.

2. Materials and Methods

2.1. Study Population

Between May 2010 and October 2020, 101 consecutive patients with HCM who had arrhythmia-related symptoms were admitted to the Arrhythmia Center, Fuwai Hospital,
Beijing, for electrophysiological evaluation. The symptoms included palpitations, syncope, or presyncope. The final inclusion criteria included: (1) diagnosed with HCM; (2) primary SND or AVB. The exclusion criteria included: (1) secondary AVB due to ventricular septal myectomy or percutaneous septal alcohol ablation; (2) secondary SND or AVB due to drugs, intrinsic diseases other than cardiomyopathy, or extrinsic causes listed in the current HCM guidelines [6]. Whether the bradyarrhythmia was primary or secondary was adjudicated by three independent reviewers, two electrophysiologists from the Arrhythmia Center, and one expert from the Cardiomyopathy Center. This was conducted through a detailed chart review. This study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board and ethics committee on 6 December 2021 (Approval No. 2021-1574). Informed consent was obtained from all participants.

2.2. Diagnosis of HCM

HCM was defined by a wall thickness $\geq 15$ mm in one or more left ventricular myocardial segments measured by echocardiography and/or cardiovascular magnetic resonance imaging (MRI), which was not explained solely by loading conditions [1,2]. In patients with intensive physical training, hypertension, or valve diseases, the diagnosis was made by at least two experts from the Cardiomyopathy Center based on additional information, including family history, noncardiac symptoms and signs, ECG abnormalities, laboratory tests, and multimodality cardiac imaging, especially cardiac MRI. In this study, all patients were evaluated by echocardiography, and nearly half of them were also assessed by cardiac MRI. Left ventricular outflow tract obstruction was defined as an instantaneous peak Doppler left ventricular outflow tract pressure gradient of $\geq 30$ mmHg [1,2]. A gradient $\geq 50$ mmHg was considered hemodynamically significant [1,2].

2.3. Diagnosis of SND and AVB

Bradyarrhythmias included in this study were SND and AVB. Bundle branch block was not included in this study. SND included sinus bradycardia and sinus node arrest. AVB included first-degree, second-degree, and third-degree AVB. At least two electrophysiologists made the diagnosis based on ECG and Holter monitoring.

2.4. Follow-Up

Patients were followed up by outpatient visits or telephone calls at 3 months, 6 months, 12 months, and every year thereafter. All-cause deaths and cardiac death events were recorded. The final census date for this study was 15 December 2021.

2.5. Statistical Analysis

Continuous variables are expressed as mean $\pm$ standard deviation (SD) or median (interquartile range (IQR)) as appropriate. Categorical parameters are shown as ratios or percentages. The Student’s t-test or Mann–Whitney U test was conducted between two independent samples as appropriate for continuous data. The chi-square test was used for categorical data. A $p$-value of $<0.05$ was considered statistically significant. Data analyses were performed using R version 4.0.2.

3. Results

3.1. The Spectrum of Arrhythmias

Figure 1 displays the spectrum of all arrhythmias. Of all 101 patients, 97 had arrhythmias, 35 had bradyarrhythmias, and 29 had primary bradyarrhythmias. Of the six patients with secondary third-degree AVB, five were due to the Morrow procedure, and one was due to percutaneous septal radiofrequency ablation. Of the 29 patients with primary bradyarrhythmias, 15 (51.7%) only had SND, 12 (41.4%) only had AVB, and two (6.9%) had both.
due to percutaneous septal radiofrequency ablation. Of the 29 patients with primary bradyarrhythmias, 15 (51.7%) only had SND, 12 (41.4%) only had AVB, and two (6.9%) had both.

Of the 17 patients with SND, 12 had sinus bradycardia, six had sinus arrest, and one had both sinus bradycardia and sinus arrest. Of the 14 patients with AVB, five had first-degree AVB, seven had second-degree AVB, and five had third-degree AVB.

3.2. Baseline Characteristics of Patients with Bradyarrhythmias

The demographic and clinical features of all patients with primary bradyarrhythmias are shown in Table 1. In the overall cohort, 20 (69%) patients were male, and the median (IQR) age at admission was 62 (32.5) years old. Fifteen (51.7%) patients had a history of syncope, and one (3.4%) had a family history of HCM. Hypertension was the most frequent (48.3%) comorbid disease. Cardiac MRI was performed in 12 patients, and late gadolinium enhancement was detected in 10 of these patients.
Table 1. Demographic and clinical characteristics.

| Parameters                        | Overall (n = 29) | SND (n = 17) | AVB (n = 14) |
|-----------------------------------|-----------------|-------------|-------------|
| Male gender, n (%)                | 20 (69.0)       | 11 (64.7)   | 11 (78.6)   |
| Weight, kg                        | 67 ± 11.8       | 66 ± 12.6   | 67 ± 11.7   |
| Height, cm                        | 168 ± 6.6       | 168 ± 6.9   | 169 ± 6.3   |
| BSA, m²                           | 1.75 ± 0.17     | 1.74 ± 0.17 | 1.76 ± 0.16 |
| BMI, kg/m²                        | 23.5 ± 3.42     | 23.4 ± 3.68 | 23.3 ± 3.39 |
| Age at admission, y               | 62 (32.5)       | 65 (18.5)   | 56 (32.5)   |
| Age at arrhythmia symptom onset, y| 54 (30.0)       | 55 (28.0)   | 50 (27.0)   |
| History of syncope, n (%)         | 15 (51.7)       | 9 (52.9)    | 7 (36.8)    |
| Family history of HCM, n (%)      | 1 (3.4)         | 0 (0)       | 1 (3.4)     |
| Comorbidities, n (%)              | 19 (65.5)       | 12 (70.6)   | 8 (57.1)    |
| HTN, n (%)                        | 14 (48.3)       | 9 (52.9)    | 6 (42.9)    |
| CAD, n (%)                        | 7 (24.1)        | 4 (23.5)    | 3 (21.4)    |
| DM, n (%)                         | 3 (10.3)        | 1 (5.9)     | 2 (14.3)    |
| CHD, n (%)                        | 0 (0)           | 0 (0)       | 0 (0)       |
| VHD, n (%)                        | 0 (0)           | 0 (0)       | 0 (0)       |
| PH, n (%)                         | 3 (10.3)        | 1 (5.9)     | 3 (21.4)    |
| History of Stroke, n (%)          | 1 (3.4)         | 1 (5.9)     | 0 (0)       |
| NYHA-FC, n (%)                    | 25 (86.2)       | 15 (88.2)   | 11 (78.6)   |
| HCM symptom-improving therapy at |                |             |             |
| discharge                          |                |             |             |
| Beta-blockers                     | 20 (69.0)       | 12 (70.6)   | 8 (51.7)    |
| Non-DHP CCB                       | 3 (10.3)        | 3 (17.6)    | 0 (0)       |

SND, sinus node dysfunction; AVB, atrioventricular block; BSA, body surface area; BMI, body mass index; HCM, hypertrophic cardiomyopathy; HTN, hypertension; CAD, coronary artery disease; DM, diabetes mellitus; CHD, congenital heart disease; VHD, valvular heart disease; PH, pulmonary hypertension; NYHA-FC, New York Heart Association functional class; Non-DHP CCB, Non-dihydropyridine calcium channel blocker. Values are expressed as n (%), ratio, mean ± SD, or median (interquartile range).

The echocardiography parameters are displayed in Table 2. The multisegment (48.3%) and interventricular septum (37.9%) comprised the majority of hypertrophic types. Six (20.7%) patients had left ventricular obstructive outflow tract obstruction. The mean maximum left ventricular wall thickness was 24.3 ± 4.3 mm. Most patients had a normal systolic function with a median (IQR) left ventricular ejection fraction of 63% (10.0).

Table 2. Echocardiography parameters.

| Parameters                        | Overall (n = 29) | SND (n = 17) | AVB (n = 14) |
|-----------------------------------|-----------------|-------------|-------------|
| HCM types                          |                |             |             |
| IVS hypertrophy                    | 11 (37.9)      | 6 (35.3)    | 6 (42.9)    |
| Apex hypertrophy                   | 4 (13.8)       | 4 (23.5)    | 0 (0)       |
| Multisegment hypertrophy           | 14 (48.3)      | 7 (41.2)    | 8 (57.1)    |
| LVOT obstruction, n(%)             | 6 (20.7)       | 6 (35.3)    | 0 (0)       |
| Ejection fraction, %               | 63 (10.0)      | 65 (11.5)   | 60 (13.5)   |
| LA dimension (AP), mm              | 41 (7.0)       | 41 (9.0)    | 40 (4.8)    |
| LVEDD, mm                          | 47 ± 6.8       | 46 ± 6.2    | 49 ± 8.9    |
| Maximum LV thickness, mm           | 20 ± 4.3       | 19 ± 4.6    | 21 ± 3.7    |
| Mitral regurgitation ≥ moderate, n (%) | 2 (6.9) | 2 (9.5)    | 1 (6.3)     |

SND, sinus node dysfunction; AVB, atrioventricular block; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LVOT, left ventricular outflow tract; LA, left atria; AP, anteroposterior; LVEDD, left ventricular end-diastolic dimension; LV, left ventricle. Values are expressed as n (%), ratio, mean ± SD, or median (interquartile range).

Comparisons of all the baseline characteristics between the two groups are shown in Table 3. More patients with SND had left ventricular obstructive outflow tract obstruction...
than those with AVB ($p = 0.013$). Other clinical features were comparable between the two groups.

### Table 3. Comparisons between patients with SND and patients with AVB.

| Parameters                                      | SND Only ($n = 15$) | AVB Only ($n = 12$) | $p$ Value |
|-------------------------------------------------|---------------------|---------------------|-----------|
| Male gender, n(%)                               | 9 (60.0)            | 9 (75.0)            | 0.411     |
| Weight, kg                                      | 67 ± 12.3           | 68 ± 10.9           | 0.817     |
| Height, cm                                      | 168 ± 7.1           | 169 ± 6.6           | 0.574     |
| BSA, $m^2$                                      | 1.75 ± 0.17         | 1.77 ± 0.16         | 0.693     |
| BMI, kg/$m^2$                                   | 23.8 ± 3.53         | 23.7 ± 3.15         | 0.965     |
| Age at admission, y                             | 66 (13.0)           | 56 (39.0)           | 0.252     |
| Age at arrhythmia symptom onset, y              | 62 (26.0)           | 50 (29.0)           | 0.704     |
| History of syncope, n(%)                        | 8 (53.3)            | 6 (50.0)            | 0.863     |
| Family history of HCM, n(%)                     | 0 (0)               | 1 (8.3)             | 0.255     |
| Comorbidities, n(%)                             |                     |                     |           |
| HTN, n(%)                                       | 8 (53.3)            | 5 (41.7)            | 0.547     |
| CAD, n(%)                                       | 4 (26.7)            | 3 (25.0)            | 0.922     |
| DM, n(%)                                        | 1 (6.7)             | 2 (16.7)            | 0.411     |
| CHD, n(%)                                       | 0 (0)               | 0 (0)               | N/A       |
| VHD, n(%)                                       | 0 (0)               | 0 (0)               | N/A       |
| PH, n(%)                                        | 0 (0)               | 2 (16.7)            | 0.100     |
| History of Stroke, n(%)                         | 1 (6.7)             | 0 (0)               | 0.362     |
| NYHA-FC, n(%)                                   | 14 (93.3)           | 10 (83.3)           | 0.268     |
| I/II                                            |                     |                     |           |
| III/IV                                          | 1 (6.7)             | 2 (16.7)            |           |
| HCM symptom improving therapy                   |                     |                     |           |
| Beta-blockers                                   | 12 (80.0)           | 8 (66.7)            | 0.432     |
| Non-DHP-CCB                                     | 3 (20.0)            | 0 (0)               | 0.100     |
| Echocardiography parameters                     |                     |                     |           |
| HCM types                                       |                     |                     | 0.150     |
| IVS hypertrophy                                 | 5 (33.3)            | 5 (41.7)            |           |
| Apex hypertrophy                                | 4 (26.7)            | 0 (0)               |           |
| Multi-segment hypertrophy                       | 6 (40.0)            | 7 (58.3)            |           |
| LVOT Obstruction, n(%)                          | 6 (40.0)            | 0 (0)               | 0.013     |
| Ejection fraction, %                            | 65 (8.0)            | 61 (10.0)           | 0.252     |
| LA dimension (AP), mm                           | 41 (11.0)           | 40 (6.3)            | 0.696     |
| LVEDD, mm                                       | 46 ± 3.8            | 50 ± 7.2            | 0.126     |
| Max LV thickness, mm                            | 19 ± 4.6            | 21 ± 3.9            | 0.247     |

SND, sinus node dysfunction; AVB, atrioventricular block; BSA, body surface area; BMI, body mass index; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LVOT, left ventricular outflow tract; LA, left atrial; AP, anteroposterior; LVEDD, left ventricular end-diastolic dimension; LV, left ventricle; HTN, hypertension; CAD, coronary artery disease; DM, diabetes mellitus; CHD, congenital heart disease; VHD, valvular heart disease; PH, pulmonary hypertension; NYHA-FC, New York Heart Association functional class; Non-DHP CCB, Non-dihydropyridine calcium channel blocker; N/A, not applicable. Values are expressed as n (%), ratio, mean ± SD, or median (interquartile range). Comparisons between the two groups: student t-test or Mann-Whiney U test for continuous data, and chi-square test for categorical data.

The baseline characteristics were also compared between male and female patients (Table 4). Male patients had greater levels of weight, height, and body surface area than female patients, as expected. More male patients had coronary artery disease than female patients ($p = 0.042$). Male patients seemed to have greater maximum left ventricular wall thickness than female patients with a borderline significant trend ($p = 0.067$). Other clinical features were comparable between the two groups.
Table 4. Comparisons between male and female patients.

| Parameters                       | Male (n = 20) | Female (n = 9) | p Value |
|----------------------------------|---------------|---------------|---------|
| Weight, kg                       | 70 ± 11.9     | 61 ± 9.0      | 0.048   |
| Height, cm                       | 171 ± 5.0     | 162 ± 5.2     | <0.001  |
| BSA, m²                          | 1.81 ± 1.15   | 1.62 ± 0.12   | 0.002   |
| BMI, kg/m²                       | 23.7 ± 3.63   | 23.1 ± 3.03   | 0.639   |
| Age at admission, y              | 59 ± 20.5     | 57 ± 13.2     | 0.833   |
| Age at arrhythmia symptom onset, y| 55 ± 18.7     | 47 ± 13.5     | 0.256   |
| History of syncope, n(%)         | 11 (55.0)     | 4 (44.4)      | 0.599   |
| Family history of HCM, n(%)      | 0 (0)         | 1 (11.1)      | 0.129   |
| Comorbidities, n(%)              |               |               |         |
| HTN, n(%)                        | 11 (55.0)     | 3 (33.3)      | 0.280   |
| CAD, n(%)                        | 7 (35.0)      | 0 (0)         | 0.042   |
| DM, n(%)                         | 2 (10.0)      | 1 (11.1)      | 0.928   |
| CHD, n(%)                        | 0 (0)         | 0 (0)         | N/A     |
| VHD, n(%)                        | 0 (0)         | 0 (0)         | N/A     |
| PH, n(%)                         | 3 (15.0)      | 0 (0)         | 0.220   |
| History of Stroke, n(%)          | 0 (0)         | 1 (11.1)      | 0.129   |
| NYHA-FC, n(%)                    |               |               | 0.164   |
| I/II                             | 18 (90.0)     | 7 (77.8)      | 0.491   |
| III/IV                           | 2 (10.0)      | 2 (22.2)      | 0.928   |
| HCM symptom improving therapy    |               |               |         |
| Beta-blockers                    | 13 (65.0)     | 7 (77.8)      | 0.491   |
| Non-DHP-CCB                      | 2 (10.0)      | 1 (11.1)      | 0.928   |
| Echocardiography parameters      |               |               |         |
| HCM types                        | 0.491         |               |         |
| IVS hypertrophy                  | 7 (35.0)      | 4 (44.4)      |         |
| Apex hypertrophy                 | 2 (10.0)      | 2 (22.2)      |         |
| Multi-segment hypertrophy        | 11 (55.0)     | 3 (33.3)      |         |
| LVOT Obstruction, n(%)           | 4 (20.0)      | 2 (22.2)      | 0.891   |
| Ejection fraction, %             | 64 (10.7)     | 62 (11.5)     | 0.321   |
| LA dimension (AP), mm            | 41 ± 7.3      | 39 ± 11.1     | 0.538   |
| LVEDD, mm                        | 46 ± 7.6      | 49 ± 4.3      | 0.280   |
| Max LV thickness, mm             | 21 ± 4.4      | 18 ± 3.4      | 0.067   |
| Mitral regurgitation ≥moderate, n(%)| 2 (10.0)  | 0 (0)        | 0.587   |

BSA, body surface area; BMI, body mass index; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LVOT, left ventricular outflow tract; LA, left atrial; AP, anteroposterior; LVEDD, left ventricular end-diastolic dimension; LV, left ventricle; HTN, hypertension; CAD, coronary artery disease; DM, diabetes mellitus; CHD, congenital heart disease; VHD, valvular heart disease; PH, pulmonary hypertension; NYHA-FC, New York Heart Association functional class; Non-DHP CCB, Non-dihydropyridine calcium channel blocker; N/A, not applicable. Values are expressed as n(%), ratio, mean ± SD, or median (interquartile range). Comparisons between the two groups: student t-test or Mann-Whiney U test for continuous data, and chi-square test for categorical data.

3.3. Treatment and Outcomes

A total of 22 patients received pacemaker implantation, including 17 (77.3%) dual-chamber pacing, four (18.2%) single-chamber ventricular pacing, and one (4.5%) cardiac resynchronization therapy. The reasons for pacemaker implantation were AVB in 12 patients, SND in 10 patients, and none for improving HCM-related symptoms. At discharge, 20 (69.3%) patients received beta-blockers, and three (10.3%) patients received non-dihydropyridine calcium channel blockers to improve HCM-related symptoms (Table 1). There were no death events during follow-up.

4. Discussion

HCM is one of the leading causes of sudden cardiac death in youths and athletes. Arrhythmias may cause palpitations, syncope, or presyncope in patients with HCM. Syncope could be caused by ventricular tachycardia, supraventricular tachycardia, or bradyarrhythmias, including SND and AVB. Although ventricular fibrillation is the most commonly recorded fatal arrhythmic event, asystole and AVB have been reported [2]. Primary brad-
yarrhythmias were believed to be uncommon in patients with HCM, and hence are understudied. This study aimed to comprehensively analyze different types of primary bradyarrhythmias in a tertiary-based HCM population in China. The results indicate that more than a quarter (29/101) of the patients with arrhythmia-related symptoms had primary bradyarrhythmias. The prevalences of SND and AVB were similar.

Our study shows that some patients with symptomatic SND and AVB required pacemaker implantation. There are many studies on pacemaker implantation in patients with HCM, in which the indications are improving the HCM-related symptoms or secondary third-degree AVB. There are case reports on patients with HCM and primary third-degree AVB [7–9]. In a study by Barriales-Villa and colleagues [10], of 48 patients with HCM who received pacemaker implantation, 20 had SND (16 were primary, and four were secondary), and 28 had AVB (20 were primary, and eight were secondary). Another study [11] included 70 patients with HCM who received a pacemaker implantation, and 22 (31%) of them were due to bradyarrhythmias. Of the 22 patients, 12 were AVB, six were SND, and four were atrial fibrillation with a slow ventricular rate. However, the authors did not mention how many patients had primary or secondary bradyarrhythmias.

Higuchi et al. reported that 96 (23.2) of the 414 patients with HCM had first-degree AVB [12]. In the present study, the figure for first-degree AVB was 5%, which might be greater if we expanded the population to the general HCM population.

The presence of AVB might be related to particular genetic subtypes in younger patients. In this study, we could not obtain genotype information. However, patients with AVB in this study were older, with a median age of 56 years.

5. Limitations

This study had several limitations. Firstly, there was patient selection bias because this was a retrospective analysis from a single tertiary arrhythmia center. The population enrolled did not represent the general HCM population. Secondly, the sample size was small, although this was a 10-year analysis. Thirdly, genotype information was not available in the present study, which might be important for classifying the etiology of HCM. Lastly, in this study, patients had a mean age of 62 years, and we could not rule out the association between age and bradyarrhythmias. Further multicenter studies of primary bradyarrhythmias in the general HCM population are needed.

6. Conclusions

Primary bradyarrhythmias need to be evaluated in HCM patients with arrhythmia-related symptoms. Patients with HCM might need a pacemaker implantation for primary bradyarrhythmias.

Author Contributions: Conceptualization, H.-D.Z., M.T. and J.-T.Z.; Data curation, H.-D.Z., M.T. and J.-T.Z.; Formal analysis, H.-D.Z., M.T. and J.-T.Z.; Funding acquisition, H.-D.Z., M.T. and J.-T.Z.; Investigation, H.-D.Z., M.T. and J.-T.Z.; Methodology, H.-D.Z., M.T. and J.-T.Z.; Project administration, H.-D.Z., M.T. and J.-T.Z.; Resources, H.-D.Z., M.T. and J.-T.Z.; Software, H.-D.Z. and J.-T.Z.; Supervision, H.-D.Z., M.T. and J.-T.Z.; Validation, H.-D.Z., M.T. and J.-T.Z.; Visualization, H.-D.Z. and J.-T.Z.; Writing—Original draft, H.-D.Z.; Writing—Review and editing, H.-D.Z., M.T. and J.-T.Z. All authors have read and agreed to the published version of the manuscript.

Funding: The study was supported by the National Natural Science Foundation of China (82000064 and U1913210). The funding source had no role in study design; in the collection, analysis, and interpretation of data; in writing the report; and in the decision to submit the article for publication.

Institutional Review Board Statement: This study was performed in accordance with the Declaration of Helsinki and was approved by the Review Board and ethics committee of Fuwai Hospital on 6 December 2021 (Approval No. 2021-1574).

Informed Consent Statement: Informed consent was obtained from all participants.
Data Availability Statement: Research data is confidential. Data sharing requests are required to meet the policies of the hospital and the funder.

Conflicts of Interest: The authors declare that there is no conflict of interest.

References
1. Ommen, S.R.; Mital, S.; Burke, M.A.; Day, S.M.; Deswal, A.; Elliott, P.; Evanovich, L.L.; Hung, J.; Joglar, J.A.; Kantor, P.; et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020, 142, e558–e631. [PubMed]
2. Elliott, P.M.; Anastasakis, A.; Borger, M.A.; Borggrefe, M.; Cecchi, F.; Charron, P.; Hagege, A.A.; Lafont, A.; Limongelli, G.; Mahrholdt, H.; et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014, 35, 2733–2779. [PubMed]
3. Zhang, H.D.; Ding, L.; Weng, S.X.; Zhou, B.; Ding, X.T.; Hu, L.X.; Qi, Y.J.; Yu, F.Y.; Feng, T.J.; Zhang, J.T.; et al. Characteristics and Long-Term Ablation Outcomes of Supraventricular Arrhythmias in Hypertrophic Cardiomyopathy: A 10-Year, Single-Center Experience. Front. Cardiovasc. Med. 2021, 8, 766571. [CrossRef] [PubMed]
4. Maron, B.J. Clinical Course and Management of Hypertrophic Cardiomyopathy. N. Engl. J. Med. 2018, 379, 655–668. [CrossRef] [PubMed]
5. Cui, H.; Schaff, H.V.; Nishimura, R.A.; Geske, J.B.; Dearani, J.A.; Lahr, B.D.; Ommen, S.R. Conduction Abnormalities and Long-Term Mortality Following Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2019, 74, 645–655. [CrossRef] [PubMed]
6. Kusumoto, F.M.; Schoenfeld, M.H.; Barrett, C.; Edgerton, J.R.; Ellenbogen, K.A.; Gold, M.R.; Goldschlager, N.F.; Hamilton, R.M.; Joglar, J.A.; Kim, R.J.; et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2019, 140, e382–e482.
7. Yesil, M.; Bayata, S.; Susam, I.; Dinçkal, H.; Postaci, N. Rare association of hypertrophic cardiomyopathy and complete atrioventricular block with prompt disappearance of outflow gradient after DDD pacing. EP Eur. 1999, 1, 280–282. [CrossRef] [PubMed]
8. Zhang, L.; Cheng, X.; Chen, J.; Zhou, M.; Qian, T.; Zhang, Z.; Yin, J.; Zhang, H.; Dai, G.; Qin, Y.; et al. Left Bundle Pacing for Left Bundle Branch Block and Intermittent Third-Degree Atrioventricular Block in a MYH7 Mutation-Related Hypertrophic Cardiomyopathy With Restrictive Phenotype in a Child. Front. Pediatr. 2020, 8, 312. [CrossRef] [PubMed]
9. Doven, O.; Cicek, D.; Pekdemir, H.; Camsari, A.; Parmaksiz, T.; Cin, G.V.; Akkus, N.M. Abnormal His-Purkinje system conduction leading to complete atrioventricular block in patients with hypertrophic cardiomyopathy: A report of 3 cases. Jpn. Heart J. 2004, 45, 347–352. [CrossRef] [PubMed]
10. Barrales-Villa, R.; Centurión-Inda, R.; Fernández-Fernández, X.; Ortiz, M.F.; Pérez-Alvarez, L.; Rodríguez García, I.; Hermida-Prieto, M.; Monserrat, L. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. Rev. Esp. Cardiol. 2010, 63, 985–988. [CrossRef]
11. Valzania, C.; Gadler, F.; Boriani, G.; Rapestiz, C.; Eriksson, M.J. Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: Single center implant data extracted from the Swedish pacemaker and ICD registry. Scand. Cardiovasc. J. SCJ 2020, 54, 239–247. [CrossRef]
12. Higuchi, S.; Minami, Y.; Shoda, M.; Shirotani, S.; Saito, C.; Haruki, S.; Gotou, M.; Yagishita, D.; Ejima, K.; Hagiwara, N. Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy. J. Am. Heart Assoc. 2020, 9, e015064. [CrossRef] [PubMed]